Concepedia

Publication | Closed Access

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

DOI

137

Citations

22

References

2011

Year

Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife, B. Anghan, Antonin Lévy, Ian Judson, Johann S. de Bono, Jean‐Charles Soria, Stan B. Kaye, Xavier Paolettí
Journal of Clinical Oncology

Abstract

Moderate and severe toxicities occur regularly after the first cycle in phase I trials of MTAs and may deserve increased attention in the RP2D process for these agents.

References

YearCitations

Page 1